SUCLG2 and acute myeloid leukemia: As an independent validation to evaluate SUCLG activity in AML subtypes, we used SUCLG1 and SUCLG2-directed shRNAs to downregulate their expression in FLT3-wt (HL60 and K562) and FLT3-ITD+ AMLs (MOLM13 and MV411) (Supplementary Fig. 2g).